Heparin-induced thrombocytopaenia.
Research article published in Postgraduate medical journal (2018)
Abstract
Heparin-induced thrombocytopaenia (HIT) is a severe and potentially life-threatening adverse drug reaction. Patients become extremely hypercoagulable, and this can lead to life-threatening and limb-threatening thrombosis with a mortality of 5%-10%. HIT is an antibody-mediated process in which platelet activation occurs. Diagnosis requires a high index of suspicion along with a scoring system and laboratory testing. Patients suspected of having HIT must not receive any further heparin or low-molecular weight heparin and must be started on an alternative anticoagulant such as argatroban or danaparoid. Fondaparinux may also be considered but is not licenced for this indication.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Heparin-induced thrombocytopaenia.
Why This Matters for Hirudotherapy
This concise review describes heparin-induced thrombocytopaenia (HIT) as a severe antibody-mediated adverse reaction that paradoxically renders patients hypercoagulable with a stated mortality of 5%-10%, requiring immediate cessation of all heparin and switching to alternative anticoagulants such as argatroban or danaparoid. The hirudotherapy connection is that HIT is a known limitation of heparin-based anticoagulation, and historically hirudin and its derivatives (direct thrombin inhibitors needing no heparin) were investigated as heparin-free alternatives in such settings, tying back to the leech secretome's pharmacological legacy. As an honest caveat, this is a brief clinical overview that does not mention leeches or hirudin and recommends specific non-leech agents, so it provides background on why heparin alternatives matter rather than direct evidence for leech therapy.
Citation
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026